81.30
+2.65%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TTY Biopharm Co
Its shares trade on Taipei Exchange under the ticker 4105.TWO. It has been listed since 27 September 2001. In the fiscal year to 31 December 2025, it reported revenue of TWD 6.45bn and net income of TWD 1.56bn. At that date it held total assets of TWD 11.35bn and shareholders' equity of TWD 7.24bn.
TTY Biopharm Co. Ltd. engages in the business of producing pharmaceuticals and chemical drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2001-09-27. The firm mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Sept 2001
- Website
- tty.com.tw ↗
Leadership
Pay as last reported
- Mr. C. LinChairman of the Board, since 2011TWD 12.2m
- Ms. Wen-Hwa ChangVice Chairman of the Board, since 1995TWD 3.1m
- Mr. Kuo-Chiang ChangChief Financial Officer, Corporate Governance Officer, Head of Finance
- Ms. Shu-Fen HuangChief Compliance Officer, Chief Legal Affairs Officer
- Ms. Ching-Lan HouGeneral Manager
- Mr. Cheng-Yi PengDeputy General Manager-Formulation R&D Center
- Mr. Yu-Wen WangSenior Deputy General Manager-Cancer Science Development Group and Corporate Development Division
- Weiquan WangManager of Accounting
- Mr. Chia-Pin HsiaoDirectorTWD 456,000
- Mr. Ted HsuDirector
- Ms. Ying-Ying LiaoDirectorTWD 2.3m
- Mr. Tze-Chiang YangDirectorTWD 2.3m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TTY Biopharm produces oncology medicines and anti-infective medicines for global markets.
- The firm operates six business segments including Cancer Drug and Healthcare.
- Main products include anti-cancer drugs and influenza vaccines for patients.
Weaknesses
- The company is headquartered in Taipei City, Taiwan, limiting local reach.
- Listed on 27 September 2001, which may affect investor perception.
- Reliance on domestic markets reduces immediate international revenue diversification.
Opportunities
- Expanding Mainland Medical Drug segment offers growth in China.
- Distributing products in overseas markets increases global brand visibility.
- Increasing demand for gastrointestinal health care medicines supports segment growth.
Threats
- Competition in the Anti-Infective Drug segment may lower margins.
- Regulatory changes in Taiwan could impact domestic sales significantly.
- Economic shifts in overseas markets might reduce export volumes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.